Apotea AB (publ) (STU:V30) EBIT: €28.5 Mil (TTM As of Mar. 2026)


STU:V30 Apotea AB (publ) STU:V30
18 GF Score
Price €6.77
! 1 Warning Sign
View Full Analysis

What is Apotea AB (publ) EBIT?

Apotea AB (publ) STU:V30 +0.74% 18 EBIT is €28.5 Mil as of Mar. 2026. GuruFocus rates STU:V30 with a GF Score™ of 18/100. The stock has 1 warning sign investors should review.

Apotea AB (publ)'s earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was €9.5 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was €28.5 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Apotea AB (publ)'s annualized ROC % for the quarter that ended in Mar. 2026 was 24.14%. Apotea AB (publ)'s annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 40.18%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Apotea AB (publ)'s Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 3.96%.

Apotea AB (publ)  (STU:V30) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Apotea AB (publ)'s annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=37.62 * ( 1 - 21.28% )/( (120.608 + 124.702)/ 2 )
=29.614464/122.655
=24.14 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=181.992 - 58.572 - ( 2.812 - max(0, 80.084 - 102.781+2.812))
=120.608

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=206.177 - 71.755 - ( 9.72 - max(0, 97.175 - 130.736+9.72))
=124.702

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Apotea AB (publ)'s annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=37.988/( ( (74.662 + max(24.195, 0)) + (70.734 + max(19.487, 0)) )/ 2 )
=37.988/( ( 98.857 + 90.221 )/ 2 )
=37.988/94.539
=40.18 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(32.658 + 59.905 + 4.162) - (58.572 + 0 + 13.958)
=24.195

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(34.443 + 76.527 + 0.00099999999997635) - (71.755 + 0 + 19.729)
=19.487

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Apotea AB (publ)'s Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=28.485/719.311
=3.96 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Apotea AB (publ) EBIT Related Terms

Apotea AB (publ) EBIT Historical Data

* Premium members only.

The historical data trend for Apotea AB (publ)'s EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Apotea AB (publ) EBIT Chart

Apotea AB (publ) Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
13.08 3.17 10.13 23.47 27.73

Apotea AB (publ) Quarterly Data
Dec21 Dec22 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.49 8.55 8.13 2.32 9.50

Apotea AB (publ) EBIT Competitor Comparison

For the Pharmaceutical Retailers subindustry, Apotea AB (publ)'s EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Apotea AB (publ) EV-to-EBIT vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Apotea AB (publ)'s EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Apotea AB (publ)'s EV-to-EBIT falls into.


STU:V30
18GF Score
Apotea AB (publ) STU:V30
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Apotea AB (publ) EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €28.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of €28.5 Mil mean?
Apotea AB (publ) (STU:V30) has a EBIT of €28.5 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Apotea AB (publ).
Is Apotea AB (publ)'s EBIT too high?
Apotea AB (publ)'s current EBIT is €28.5 Mil. Overall, Apotea AB (publ) has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Apotea AB (publ)'s EBIT compare to competitors?
Apotea AB (publ)'s EBIT of €28.5 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Healthcare Providers & Services company?
A good EBIT depends on the Healthcare Providers & Services industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Apotea AB (publ). Apotea AB (publ)'s current EBIT is €28.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apotea AB (publ) stock overvalued right now?
Apotea AB (publ) (STU:V30) has a current EBIT of €28.5 Mil. The current EBIT is €28.5 Mil. Apotea AB (publ)'s overall GF Score™ is 18/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Apotea AB (publ) (STU:V30), the current EBIT is €28.5 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Apotea AB (publ) Business Description

Other Exchanges APOTEA:Sweden
Address Sveavagen 168, Stockholm, SWE, 11346
Apotea AB (publ) is engaged in the online pharmacy with fast deliveries, good prices and a large selection. Its vision is to be tomorrow's pharmacy by constantly facilitating and simplifying for the customer.
18GF Score

Get the complete analysis for STU:V30

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.77
Price